ArticleAmerican journal of cancer research2024

Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.

Po-Ting Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.